AbbVie’s Dividend Keeps Climbing. Is It Still a Buy for Income Investors?

AbbVie's stock has surged nearly 29% this year, but a rising share price compresses the yield even as the dividend keeps growing. Before adding shares for income, consider what the pending Apogee deal and lingering debt load could mean for the payout's future.